



GAU 1645
JFW

PATENT

Attorney Docket No.: A-72186-1/TAL/DCF

Attorney File No.: 471702-00008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

QI *et al.*

Serial No. 10/804,763

Filing Date: March 19, 2004

For: *Gene Therapy Vectors Having
Reduced Immunogenicity*


Examiner: Not Yet Assigned

Art Unit: 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Dated: July 20, 2004

Signed: 
Brent Yonchura

**INFORMATION DISCLOSURE STATEMENT
AND
STATEMENT OF RELATEDNESS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1273 Off. Gaz. Pat. Off. 1, 8/5/2003, no copies of U.S. patents and U.S. published applications are enclosed.

Further, in satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and as required by M.P.E.P. § 2001.06(b), Applicant notes that the present application is related to the following pending patent applications:

1. U.S.S.N. 10/804,762, filed March 19, 2004.

Serial No. 10/804,763
Filing Date: March 19, 2004

None of the foregoing references are believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 471702-00008 [A-72186-1/TAL/DCF]).

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: July 20, 2004
Customer Number: 32940
Dorsey & Whitney LLP
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

By: David C. Foster
David C. Foster, Reg. No. 44,685 for
Todd A. Lorenz, Reg. No. 39,754

Attachments : Form PTO/SB/8A, Substitute for form 1449
11 cited references
Return Postcard



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/804,763
Filing Date	March 19, 2004
First Named Inventor	QI, Yan
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	A-72186-1/TAL/DCF (471702-00008)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,242,687	09-07-1993	Tykocinski et al.	
	A2	5,601,828	02-11-1997	Tykocinski et al.	
	A3	5,623,056	04-22-1997	Tykocinski et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO 02/102852 A2/A3	12-27-2002	Avidex Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	FINK, P., et al., "Haplotype-specific suppression of cytotoxic T cell induction by antigen inappropriately presented on T cells," <i>J. Exp. Med.</i> 157(1):141-154 (Jan. 1983).	
	C2	HAMBOR, J., et al., "CD8 functions as an inhibitory ligand in mediating the immunoregulatory activity of CD8+ cells," <i>J. Immunol.</i> 145(6):1646-1652 (Sep. 1990).	
	C3	HAMBOR, J., et al., "Regulation of allogeneic responses by expression of CD8 α -chain of stimulator cells," <i>Int. Immunol.</i> 2(9):8856-8879 (1990).	
	C4	KAPLAN, D., et al., "An immunoregulatory function for the CD8 molecule," <i>Proc. Natl. Acad. Sci. USA</i> 86(21):8512-8515 (Nov. 1989).	
	C5	KRIEGER, N., et al., "CD4+ but not CD8+ cells are essential for allojection," <i>J. Exp. Med.</i> 184(5):2013-2018 (Nov. 1996).	
	C6	QI, Y., et al., "Hybrid antibody mediated veto of cytotoxic T lymphocyte response," <i>J. Exp. Med.</i> 183(5):1973-1980 (May 1996).	
	C7	RAMMENSEE, H., et al., "Class I restricted interaction between suppressor and cytolytic cells in the response to minor histocompatibility antigens," <i>J. Immunol.</i> 132(2):668-672 (Feb. 1984).	
	C8	RAMMENSEE, H., et al., "Suppression of cell-mediated lymphocytotoxicity against minor histocompatibility antigens mediated by Lyt-1+ and Lyt-2+ T cells of stimulator strain origin," <i>Eur. J. Immunol.</i> 12(11):930-934 (Nov. 1982).	
	C9	SAMBHARA, S., et al., "Programmed cell death of T cells signaled by the T cell receptor and the α -3 domain of class I MHC," <i>Science</i> 252(5011):1424-1427 (Jun. 1991).	
	C10	STAERZ, U., et al., "Treatment of an autoimmune disease with 'classical' T cell veto: a proposal," <i>J. Clin. Immunol.</i> 19(4):195-202 (Jul. 1999).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2